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remarkably high degree of efficiency. Thus, membrane-
based or microchip-based cDNA arrays have made it possi-
ble to examine the expression of thousands of genes in the
same experiment. With robust statistical analysis for the
characterization of different patterns of altered gene
expression,2 microarray-based studies provide information
frequently described in terms borrowed from forensics (ie,
molecular “signatures,” “fingerprints,” or “profiles” of a
given disease process). Whereas the use of cDNA microar-
rays has been especially fruitful in cancer research (see Khan
et al3 and references therein), this technology has also
begun to yield basic information about healthy and dis-
eased blood vessels, including aortic aneurysms.4-7
In this issue of the Journal of Vascular Surgery,
Armstrong and colleagues8 present the results of a study
that contributes new information to our understanding of
AAAs. With tissues obtained from patients with AAAs and
atherosclerotic occlusive disease (AOD), they used a
microarray that contained 265 genes to begin developing
molecular profiles of these diseases. This is an especially
important goal with respect to AAAs in that the develop-
ment of a more comprehensive description of genes that
exhibit altered expression—both qualitatively and quanti-
tatively—may help illuminate molecular pathways that
warrant further investigation.
One of the strengths of this paper is the authors’ inclu-
sion of occlusive disease specimens along with those for
AAAs and healthy aorta and a sufficient number of samples
to encompass some of the biologic heterogeneity that
occurs in these conditions. The effort necessary to procure
an ample number of specimens for extraction of high-
quality RNA and to perform replicate analyses is a credit to
the surgeons who directed this study, especially when many
interventions used for these conditions no longer yield
pathologic tissues for examination. Although a seemingly
simple issue, thoughtful tissue procurement is particularly
important for the detection of differences between AAAs
and AOD at a molecular level of resolution.
The results presented by Armstrong et al indicate that
11 of 265 genes present on the array (4.1%) were
expressed at different levels between healthy and diseased
aortic tissues. With respect to individual genes, they found
increased expression for matrix metalloproteinase–9
(MMP-9), intercellular adhesion molecule–1, and tumor
Abdominal aortic aneurysms (AAAs) affect up to 9% of
persons over 65 years of age in the United States, and rup-
tured AAAs are responsible for approximately 15,000
deaths each year in this country alone. Although the means
to reduce deaths caused by ruptured AAAs are readily avail-
able, the overall mortality from this condition is unlikely to
change in the absence of more comprehensive diagnostic
screening. Unfortunately, population-based screening for
AAAs has met with limited enthusiasm because most AAAs
detected in screening programs are too small to warrant
repair and because there are no known forms of treatment
for patients with small asymptomatic AAAs. The lack of
therapeutic options and our inability to predict the natural
history of AAAs reflect our limited understanding of the
clinical and biologic factors that influence aneurysmal
degeneration. Fundamental knowledge of the pathophysi-
ology of AAAs therefore remains an important gap in the
basic science of vascular disease, and understanding the
mechanisms that underlie this condition is a critical goal of
vascular surgery research.1
One of the aims of contemporary basic research is to
delineate how different disorders are distinguished at the
tissue, cellular, and molecular levels. Although this may
involve hypothesis-driven studies on individual gene prod-
ucts, investigations to detect broad changes in gene expres-
sion are also of great importance. In the past, such studies
involved laborious and time-consuming techniques, with
the results requiring characterization of numerous (often
unknown) gene products. As a “spin-off” of technologies
developed to help complete the human genome sequence,
complementary DNA (cDNA) microarrays now permit
such large scale investigations to be performed with a
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necrosis factor receptor–β in both AAAs and AOD and
decreased expression of integrin α5, ephrin A5, and rho/
rac guanine nucleotide exchange factor. There was also
increased expression of laminin α4 and insulin-like growth
factor receptor–2 in AOD and decreased expression of col-
lagen VI α1, glycoprotein IIIA, and α2-macroglobulin in
AAAs. Because there were no genes specifically increased
in AAAs as compared with AOD, these findings were
interpreted to support the notion that AAAs and AOD are
similar disease processes. Emphasis was also placed on the
common alterations in genes that reflect the role of
inflammation and matrix-degrading proteinases in both
types of aortic disease.
The conclusions reached in this paper need to be con-
sidered in the context of other observations, many of
which reveal important distinctions between AAAs and
occlusive atherosclerosis. For example, the inflammatory
response in these conditions is similar in cellular composi-
tion but is quite distinct in tissue distribution, being trans-
mural in aortic aneurysms and confined to the intimal
plaque in AOD. Second, although aneurysms are typified
by the destruction of the cellular and matrix components
of the elastic media, the tunica media is usually undam-
aged in occlusive atherosclerosis. Increased expression of
MMP-9 has been particularly well documented in AAAs,
with approximately 10-fold elevations being consistently
measured at both the messenger RNA and protein levels.
In another recent study using cDNA microarrays, MMP-
9 was also found to be one of 18 genes (of 1181) upreg-
ulated in AAAs versus healthy aorta.7 Perhaps most
importantly, the expression of MMP-9 is consistently
localized to mononuclear phagocytes in the outer aortic
wall of AAAs, where its capacity for mediating elastic fiber
degradation may be particularly relevant to the patho-
physiology of aneurysmal degeneration. In contrast,
expression of MMP-9 in occlusive atherosclerosis is largely
confined to macrophages and smooth muscle cells within
the diseased intima. Thus, in determining the functional
role of MMP-9 in AAAs versus AOD, differences in
regional localization may be far more important than dif-
ferences in the overall level of messenger RNA expression.
The observations by Armstrong et al suggest a num-
ber of important avenues for further research. One obvi-
ous direction is the use of microarrays that represent a
broader spectrum of genes. Although these techniques can
involve considerable expense, commercially produced
microarrays that contain more than 10,000 genes are now
available. Secondly, it is customary to confirm the differ-
ential expression of genes identified in microarray experi-
ments with complementary techniques, such as Northern
blot analysis or quantitative reverse transcription-poly-
merase chain reaction assays, and to show whether alter-
ations in gene expression are reflected at the protein level.
Third, genes that exhibit altered expression in AAAs need
to be localized within aortic wall tissue, especially consid-
ering the substantial differences in histopathology
between AAAs and occlusive disease. Finally, additional
approaches to the statistical analysis of microarray data are
needed to make optimal progress in this area. Thus, diag-
nostic algorithms based on hierarchical “clustering” might
be used to identify gene expression patterns capable of 
distinguishing AAAs from AOD. This approach will also
be valuable in the examination of molecular alterations at
different stages of aneurysmal degeneration. The afore-
mentioned success of these approaches in cancer research
offers a valuable model for studies of vascular disease,
where gene expression profiling might be used in the clas-
sification of different subsets of aneurysmal or occlusive
disease on the basis of their molecular patterns.
Given the current expense of cDNA microarrays and
the many issues that need to be addressed in exploiting
their potential, investigators in other fields have formed
multidisciplinary research groups to facilitate progress.
An excellent example of this is the multiinstitutional
Consortium for Expression Profiling Studies in Sepsis
organized by the Genomics Group of the Trauma
Research Network. Because of their unique clinical
understanding of vascular diseases and direct access to
pathologically relevant tissues, vascular surgeons can play
a key role in embracing the “microarray revolution,”
thereby helping develop a comprehensive molecular
understanding of AAAs and other vascular disorders.
Efforts like those reported by Armstrong et al are surely
an important step towards profiling some of our most
common adversaries.
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